Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose: Raloxifene is a second-generation selective estrogen receptor modulator that reduces the incidence of breast cancer in postmenopausal women. Exemestane, a steroidal aromatase inhibitor, decreases contralateral new breast cancers in postmenopausal women when taken in the adjuvant setting. Preclinical evidence suggests a rationale for coadministration of these agents to achieve complete estrogen blockade. Experimental design: We tested the safety and tolerability of combination exemestane and raloxifene in 11 postmenopausal women with a history of hormone receptor-negative breast cancer. Patients were randomized to either raloxifene (60 mg PO daily) or exemestane (25 mg PO daily) for 2 weeks. Patients then initiated combination therapy at the same dose levels for a minimum of 1 year. Pharmacokinetic and pharmacodynamic data for plasma estrogens, raloxifene, exemestane, and their metabolites were collected at the end of single-agent therapy and during combination therapy. Results: Plasma concentration–time profiles for each drug were unchanged with monotherapy versus combination therapy. Raloxifene did not affect plasma estrogen levels. Plasma estrogen concentrations were suppressed below the lower limit of detection by exemestane as monotherapy and when administered in combination with raloxifene. The most common adverse events of any grade included arthralgias, hot flashes, vaginal dryness and myalgias. Conclusions: In this small study, coadministration of raloxifene and exemestane did not affect the pharmacokinetics or pharmacodynamics of either agent to a significant degree in postmenopausal women. The combination of estrogen receptor blockade and suppression of estrogen synthesis is well tolerated and warrants further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285

    Article  PubMed  CAS  Google Scholar 

  2. Cauley JA, Lucas FL, Kuller LH et al (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 130:270–277

    PubMed  CAS  Google Scholar 

  3. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618

    Article  PubMed  CAS  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Article  Google Scholar 

  5. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  6. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662

    PubMed  CAS  Google Scholar 

  7. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256

    Article  PubMed  CAS  Google Scholar 

  8. Cuzick J (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824

    Article  PubMed  CAS  Google Scholar 

  9. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300

    Article  PubMed  CAS  Google Scholar 

  10. Black L, Sato M, Rowley E (1994) Raloxifene (LYI39481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine by-pertrophy in ovariectomized rats. J Clin Invest 93:63–69

    Article  PubMed  CAS  Google Scholar 

  11. Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647

    Article  PubMed  CAS  Google Scholar 

  12. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  PubMed  CAS  Google Scholar 

  13. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197

    Article  PubMed  CAS  Google Scholar 

  14. Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 65:125–134

    Article  PubMed  CAS  Google Scholar 

  15. Cummings SR, Duong T, Kenyon E et al (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216–220

    Article  PubMed  CAS  Google Scholar 

  16. Lippman ME, Krueger KA, Eckert S et al (2001) Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes Of Raloxifene Evaluation study participants. J Clin Oncol 19:3111–3116

    PubMed  CAS  Google Scholar 

  17. Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–1761

    Article  PubMed  CAS  Google Scholar 

  18. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741

    Article  PubMed  CAS  Google Scholar 

  19. Gruber CJ, Tschugguel W, Schneeberger C et al (2002) Production and actions of estrogens. N Engl J Med 346:340–352

    Article  PubMed  CAS  Google Scholar 

  20. Simpson ER, Dowsett M (2002) Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 57:317–338

    Article  PubMed  CAS  Google Scholar 

  21. De Jong P, Van de Ven J, Nortier J et al (2002) Inhibition of intratumoral aromatase and estradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomized study [abstract 268]. Breast Cancer Res Treat 76:S76

    Google Scholar 

  22. de Jong P, van de Ven J, Nortier H et al (1997) Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57:2109–2111

    PubMed  Google Scholar 

  23. Buzdar A, Howell A (2001) Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 7:2620–2635

    PubMed  CAS  Google Scholar 

  24. Miller WR (1999) Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6:187–195

    Article  PubMed  CAS  Google Scholar 

  25. Miller WR, Dixon JM (2002) Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9:9–15

    PubMed  Google Scholar 

  26. Miller W, Dixon J, Grattage L, Stuart M, Hocdtin-Boes G (1999) Effects of neoadjuvant treatment with the aromatase inhibitor, anastrozole (Arimidex) on peripheral and in situ estrogen synthesis and uptake by breast tissue in postmenopausal women. Paper presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–11, 1999

  27. Miller WR, Dixon JM (2001) Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79:93–102

    Article  PubMed  CAS  Google Scholar 

  28. Geisler J, King N, Anker G et al (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089–2093

    PubMed  CAS  Google Scholar 

  29. Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751–757

    Article  PubMed  CAS  Google Scholar 

  30. Geisler J, King N, Dowsett M et al (1996) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74:1286–1291

    PubMed  CAS  Google Scholar 

  31. Coombes R, Kilburn L, Snowdon C et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570

    Article  PubMed  CAS  Google Scholar 

  32. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  PubMed  CAS  Google Scholar 

  33. The ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  Google Scholar 

  34. Lu Q, Liu Y, Long BJ et al (1999) The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57:183–192

    Article  PubMed  CAS  Google Scholar 

  35. Brodie A, Jelovac D, Long BJ (2003) Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 9:455S-459S

    PubMed  CAS  Google Scholar 

  36. Brodie A, Lu Q, Liu Y et al (1998) Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology (Huntingt) 12:36–40

    CAS  Google Scholar 

  37. Brodie AH, Mouridsen HT (2003) Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. Am J Clin Oncol 26:S17–S26

    Article  PubMed  Google Scholar 

  38. Brodie A (2003) Aromatase inhibitor development and hormone therapy: a perspective. Semin Oncol 30:12–22

    Article  PubMed  CAS  Google Scholar 

  39. Long BJ, Jelovac D, Handratta V et al (2004) Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 96:456–465

    PubMed  CAS  Google Scholar 

  40. Jelovac D, Macedo L, Handratta V et al (2004) Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res 10:7375–7381

    Article  PubMed  CAS  Google Scholar 

  41. Jelovac D, Long B, Sabnis G et al (2002) Preclinical studies evaluating the anti-tumor effects of exemestane using the intratumoral aromatase postmenopausal breast cancer model. Breast Cancer Res Treat 76:S77

    Google Scholar 

  42. Zaccheo T, Diudici D, di Salle E (1993) Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA induced mammary tumors in rats. J Steroid Biochem Mol Biol 44:677–680

    Article  PubMed  CAS  Google Scholar 

  43. di Salle E, Geroni C, Lamparelli M et al (2002) Chemopreventive effect of the aromatase inactivator exemestane combined with the antiestrogen raloxifene in the dimethylbenzanthracene (DMBA)-induced mammary tumors in rats. Am Soc Clin Oncol 21:117a

    Google Scholar 

  44. Ingle J, Suman V, Johnson P et al (1999) Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 5:1642–1649

    PubMed  CAS  Google Scholar 

  45. Rivera E, Valero V, Francis D et al (2004) Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10:1943–1948

    Article  PubMed  CAS  Google Scholar 

  46. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  PubMed  CAS  Google Scholar 

  47. Hutson PR, Love RR, Havighurst TC et al (2005) Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 11:8722–8727

    Article  PubMed  CAS  Google Scholar 

  48. Swain S, Wilson J, Eleftherios M et al (2004) Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 9:516–523

    Google Scholar 

  49. Chen Q, Ngui JS, Doss GA et al (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907–914

    Article  PubMed  CAS  Google Scholar 

  50. Johannessen DC, Engan T, Di Salle E et al (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3:1101–1108

    PubMed  CAS  Google Scholar 

  51. Cenacchi V, Baratte S, Cicioni P et al (2000) LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Pharm Biomed Anal 22:451–460

    Article  PubMed  CAS  Google Scholar 

  52. Hochner-Celnikier D (1999) Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23–29

    Article  PubMed  CAS  Google Scholar 

  53. Goss P, Bondarenko I, Manikhas G et al (2006) Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer. J Clin Oncol 24:LBA525

    Google Scholar 

  54. Langecker P, Blanchett D, Lang W et al (2002) Phase I, open-label, randomized, crossover study of the pharmacokinetic interaction of toremifene and atamestane (Biomed 777) in healthy postmenopausal women. Paper presented at Breast Cancer Res Treat, San Antonio, TX, December 11–14, 2002

  55. Masamura S, Santner SJ, Heitjan DF et al (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918–2925

    Article  PubMed  CAS  Google Scholar 

  56. Baum M, on behalf of the ATAC Trialists’ Group (2001) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat 69:210

    Google Scholar 

  57. Dowsett M, Cuzick J, Howell A et al (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and Tamoxifen Alone or in Combination’ (ATAC) trial. Br J Cancer 85:317–324

    Article  PubMed  CAS  Google Scholar 

  58. Lonning PE, Bajetta E, Murray R et al (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234–2244

    PubMed  CAS  Google Scholar 

  59. Dimitrakakis C, Zhou J, Wang J et al (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10:292–298

    Article  PubMed  Google Scholar 

  60. Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137

    Article  PubMed  CAS  Google Scholar 

  61. Vogel VG, Costantino JP, Wickerham DL et al (2003) National Surgical Adjuvant Breast and Bowel Project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 9:495S–501S

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Editorial support was provided by Gerard P. Johnson, PhD, at Complete Healthcare Communications, Inc., and was funded by Pfizer Inc. This study was partially funded by Pfizer Global Pharmaceuticals, New York, NY.

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY, 10021, USA

    T. A. Traina, M. Robson, A. Heerdt, C. Dang, D. Lake, M. Moasser, K. Panageas, L. Norton, C. Hudis & M. N. Dickler

  2. Pfizer Italia, Milan, Italy

    I. Poggesi

  3. Pfizer Inc, New York, NY, USA

    A. Asnis & B. A. Duncan

  4. Maimonides Cancer Center, Brooklyn, New York, USA

    P. Borgen

Authors
  1. T. A. Traina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Poggesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Robson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Asnis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. A. Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Heerdt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Lake
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Moasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. Panageas
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. Borgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L. Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C. Hudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M. N. Dickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. N. Dickler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Traina, T.A., Poggesi, I., Robson, M. et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 111, 377–388 (2008). https://doi.org/10.1007/s10549-007-9787-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9787-1

Keywords

Search

Navigation